Drug Profile
Research programme: malaria vaccines - PATH/Valneva
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Intercell; PATH
- Developer PATH; Valneva
- Class Antimalarials; Oligonucleotides; Parasitic vaccines; Peptides
- Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 26 Jun 2013 No development reported - Preclinical for Malaria in USA (unspecified route)
- 28 May 2013 Intercell has merged with Vivalis to form Valneva
- 16 Jan 2008 Preclinical trials in Malaria in USA (unspecified route)